// App-Quantinova.ai

3 : Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Disease Associated Interstitial Lung Disease (RECITAL): A Sub-group Analysis of a Multi-centre Randomised Controlled Trial

Researchers

Presenter

  • Toby Maher

Principal Investigators

  • Veronica Tudor

  • Peter Saunders

  • Michael Gibbons

  • Sophie Fletcher

  • Helen Parfrey

  • Chris Denton

  • Rachel Hoyles

  • Elizabeth Renzoni

  • Maria Kokosi

  • Athol Wells

  • Deborah Ashby

  • Matyas Szigeti

  • Philip Molyneaux

Medical Centers

  • University of Southern California, Los Angeles, CA

  • The Royal Marsden Hospital, London, United Kingdom

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Royal Devon and Exeter Hospital, Exeter, United Kingdom

  • Southampton General Hospital, Southampton, United Kingdom

  • Addenbrookes Hospital, Cambridge, United Kingdom

  • Kings College London, London, United Kingdom

  • Imperial College, London, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Interstitial lung disease

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • N/A

Study Id's

  • NCT01862926

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved